Gastrohepatic Disorders

On-Demand PPI Use Examined in Non-Erosive Reflux Disease, Mild Erosive Esophagitis

By September 20, 2018

Results of the study found on-demand PPI use to be superior to daily administration of a PPI (pooled OR: 0.50; 95% CI: 0.35, 0.72).

Infant PPI Use and Lung Infection Risk: Is There a Link?

By September 20, 2018

The data showed matched odds ratio for current vs past use of PPIs to be 0.88 (95% CI, 0.36 to 2.16) when comparing cases and their controls for community-acquired pneumonia. With regard to lower respiratory tract infections, the matched odds ratio between cases and their controls was 1.13 (95% CI, 0.87 to 1.48).

Tenapanor NDA Submitted for Irritable Bowel Syndrome With Constipation

By September 14, 2018

Tenapanor, a minimally-systemic small molecule, inhibits the sodium transporter NHE3 and reduces sodium absorption in the gastrointestinal tract, thus increasing intestinal fluid.

Out-of-Pocket Costs Similar for Infliximab, Infliximab-Dyyb

September 05, 2018

"Although biosimilar gap discounts begin in 2019, infliximab-dyyb may still not significantly reduce Part D beneficiaries' out-of-pocket costs given its high price and coinsurance cost-sharing similar to infliximab," the authors write.

FDA Warns of Dangers of Liquid Nitrogen in Food, Drinks

September 04, 2018

Liquid nitrogen isn't toxic, but its extremely low temperature can cause severe damage to skin and internal organs if mishandled or consumed, the FDA said in a news release.

Drinking Water Turned Off in All Detroit's Public Schools

August 31, 2018

Recent tests revealed "higher than acceptable levels... (of) copper and/or lead" in at least 1 water source - such as a fountain or sink - at 16 of 24 schools, Vitti said.

Secretagogues Compared in Irritable Bowel Syndrome With Constipation

By August 29, 2018

While several secretagogues have been recently approved by the Food and Drug Administration (FDA), a lack of head-to-head trials led researchers to conduct a systematic review to compare the effectiveness of these agents in patients with IBS-C.

Odds of Marijuana Use Up With Nausea, Vomiting in Pregnancy

August 27, 2018

The prevalence of prenatal marijuana use was 5.3% by self-report or toxicologic test findings; prevalence was greater among females with severe and mild versus no NVP (11.3 and 8.4, respectively, vs 4.5%).

Long-Term PPI Use Linked to Pneumonia Risk in Older Adults

August 24, 2018

Rate of incident pneumonia increased in second year after initiating treatment with proton pump inhibitors

Treatments for Primary Prevention of Esophageal Variceal Bleeding Compared

By August 22, 2018

Treatments (NSBB, isosorbide mononitrate, carvedilol, variceal band ligation) were compared as monotherapy or as combination therapy with each other or versus placebo.

Lenvima OK'd as First-Line Treatment for Unresectable Hepatocellular Carcinoma

By August 16, 2018

The approval was supported by findings from the multicenter, randomized, open-label, noninferiority trial, REFLECT (N=945), which included patients with previously untreated, metastatic or unresectable HCC.

FDA to Review Gimoti for Diabetic Gastroparesis in Adult Women

By August 16, 2018

The FDA has set a Prescription Drug User Fee Act target date of April 1, 2019.

Anti-MAP Therapy Beneficial in Phase 3 Crohn's Disease Trial

By August 01, 2018

The randomized, double-blind, placebo-controlled study (N=331) achieved its primary endpoint and key secondary endpoints in the intent-to-treat (ITT) population.

Iron Therapies Compared in Patients With GI-Related Iron Deficiency Anemia

By July 30, 2018

The analysis also showed that the more severe the anemia was at baseline, the greater the response was to treatment with regard to hemoglobin changes.

Coffee Consumption and Pancreatitis Risk: What's the Link?

By July 27, 2018

For this meta-analysis, researchers searched for case-control, cross-sectional, or cohort studies that included keywords such as "coffee", "caffeine", and "pancreatitis" and compared the risk of pancreatitis based on coffee consumption.

Vedolizumab SC Induces Clinical Remission in Phase 3 Ulcerative Colitis Study

By July 23, 2018

The study included 384 adult patients with moderately to severely active UC who had an inadequate response with, loss of response to, or intolerance to corticosteroids, immunomodulators, or tumor necrosis factor-alpha (TNFα)-antagonist therapy prior to being enrolled.

Opdivo + Yervoy Approved to Treat MSI-H/dMMR Metastatic Colorectal Cancer

By July 12, 2018

The approval was based on data from the ongoing Phase 2 CheckMate-142 study which enrolled patients with MSI-H/dMMR metastatic CRC who had received ≥1 prior line of therapy for metastatic disease (N=119).

Keytruda sBLA Granted Priority Review for Advanced Hepatocellular Carcinoma

By July 11, 2018

The sBLA is based on results from the Phase 2 KEYNOTE-224 trial, which enrolled 104 individuals with advanced hepatocellular carcinoma previously treated with sorafenib who were either intolerant to or showed progression of disease after treatment.

Hydralazine-Induced Hepatotoxicity Described in Case Report

By July 09, 2018

Symptoms in patients with short latency include fever, rash, and eosinophilia.

Blister Packs for Several Meds Recalled Due to Risk of Harm to Children

By July 09, 2018

The recall affects approximately 470,000 units that include drugs packaged with 3 to 10 tablets per blister card. The blister packs were developed for use in hospitals, however some were sent to retail pharmacies and were likely dispensed for in-home use.

IV Acetaminophen Minimally Helpful for Colectomy Pain

July 09, 2018

More than 1 dose of intravenous acetaminophen on postoperative day 1 was associated with lower opioid utilization (−12.4%) vs non-use, while an even stronger reduction was seen in those receiving more than one oral acetaminophen dose (−22.6%).

Occupational Exposure Limits for Heat Stress Often Exceeded: CDC

July 09, 2018

For the same 25 cases, a Heat Index screening threshold of 85 degrees Fahrenheit could identify potentially hazardous levels of workplace environmental heat when WBGT was unavailable. Six fatalities occurred when the Heat Index was <91 degrees Fahrenheit.

AMA Urges Caution With Use of Wire-Bristle BBQ Grill Brushes

July 04, 2018

Precautions should be taken, including wiping down grill after use and inspecting it for wire bristles

Gastroprotective Effects of PPIs, H2RAs Compared in Patients on DAPT

By July 03, 2018

For this study, researchers searched several large databases (from 1980 to 2016) for randomized, controlled trials (RCTs) that compared clinical outcomes in patients on DAPT taking PPIs or H2RAs.

Pembrolizumab Not Better Than Paclitaxel for Advanced Gastric Cancer

July 03, 2018

Survival no better with second-line pembrolizumab than paclitaxel for gastric, gastro-esophageal cancer

Most Bleeding Events in Non-CVD Patients Are GI-Related

June 28, 2018

The risk of a nonfatal GI bleeding event was 2.19 per 1,000 person-years in the baseline cohort, 1.77 in the non-high-risk cohort, and 1.61 in the nonmedication cohort.

Cannabinoid-Based Tx Gets Orphan Drug Designation for Autoimmune Hepatitis

By June 27, 2018

Cannabidiol is a non-psychoactive component of marijuana that does not cause intoxication or euphoria that comes from tetrahydrocannabinol.

Labeling for Nausea Drugs Used During Pregnancy Updated With New Warning

By June 27, 2018

The Warnings and Precautions section for both products has been updated to inform clinicians that there have been reports of false positive urine screening tests for methadone, opiates, and phencyclidine phosphate (PCP) with doxylamine succinate/pyridoxine hydrochloride use.

Biologic Therapies Compared in Patients With Moderate-to-Severe Crohn's Disease

By June 20, 2018

For this study, researchers identified randomized controlled trials that included adults with moderate-to-severe CD treated with various biologic agents (i.e., infliximab, adalimumab, certolizumab pegol, vedolizumab, ustekinumab) as first- or second-line therapies compared with placebo or an active comparator.

Pharmacologic Tx Should Be Used Sparingly for Reflux in Preemies

June 19, 2018

There is a lack of evidence for efficacy of pharmacologic agents and emerging evidence of significant harm; consequently, these agents should be used sparingly, if at all.